Table 2:

GWAS loci for non-response to anti-TNF biologics

Study Cohort	Chr	SNP	MA	MAF (%)	OR (95% CI)	p value
Discovery Cohort (N=589) #	5	rs34767465*	T	17.5	2.07 (1.46–2.94)	2.43×10−07
	5	rs34902560*	G	17.5	2.06 (1.45–2.93)	2.57×10−07
	5	rs13173354$	A	17.5	2.06 (1.46–2.93)	2.97×10−07
	5	rs34826562*	T	17.5	2.05 (1.44–2.90)	3.13×10−07
	5	rs6580051*	A	17.5	2.05 (1.44–2.90)	3.32×10−07
	5	rs9324761$	G	17.5	2.05 (1.44–2.90)	3.43×10−07
	5	rs6882924*	G	17.5	2.05 (1.44–2.90)	3.69×10−07
	5	rs2053309*	A	17.5	2.05 (1.44–2.90)	3.75×10−07
	5	rs11415520*	AC	17.5	2.05 (1.44–2.90)	3.75×10−07
	5	rs66483716*	G	17.5	2.05 (1.44–2.91)	3.79 ×10−07
	11	rs201833877*	T	5	3.17 (1.87–5.36)	7.18 ×10−07
Replication Cohort (N = 293)	5	rs34767465	T	23	1.8 (1.04–3.16)	0.03

^#Adjusted to azathioprine, methotrexate, antibiotics and principal component 1

^*Imputed variant

^$Variant present in the genotyping platform